Journal of Immunology Research

Journal of Immunology Research / 2007 / Article

Clinical Study | Open Access

Volume 2007 |Article ID 076396 | https://doi.org/10.1155/2007/76396

Levent Sutcigil, Cagatay Oktenli, Ugur Musabak, Ali Bozkurt, Adnan Cansever, Ozcan Uzun, S. Yavuz Sanisoglu, Zeki Yesilova, Nahit Ozmenler, Aytekin Ozsahin, Ali Sengul, "Pro- and Anti-Inflammatory Cytokine Balance in Major Depression: Effect of Sertraline Therapy", Journal of Immunology Research, vol. 2007, Article ID 076396, 6 pages, 2007. https://doi.org/10.1155/2007/76396

Pro- and Anti-Inflammatory Cytokine Balance in Major Depression: Effect of Sertraline Therapy

Academic Editor: Ethan M. Shevach
Received23 Jun 2007
Revised28 Sep 2007
Accepted28 Nov 2007
Published20 Jan 2008

Abstract

The specific associations between antidepressant treatment and alterations in the levels of cytokines remain to be elucidated. In this study, we aimed to explore the role of IL-2, IL-4, IL-12, TNF-α, TGF-β1, and MCP-1 in major depression and to investigate the effects of sertraline therapy. Cytokine and chemokine levels were measured at the time of admission and 8 weeks after sertraline treatment. Our results suggest that the proinflammatory cytokines (IL-2, IL-12, and TNF-α) and MCP-1 were significantly higher, whereas anti-inflammatory cytokines IL-4 and TGF-β1 were significantly lower in patients with major depression than those of healthy controls. It seems likely that the sertraline therapy might have exerted immunomodulatory effects through a decrease in the proinflammatory cytokine IL-12 and an increase in the anti-inflammatory cytokines IL-4 and TGF-β1. In conclusion, our results indicate that Th1-, Th2-, and Th3-type cytokines are altered in the depressed patients and some of them might have been corrected by sertraline treatment.

References

  1. T. J. Connor and B. E. Leonard, “Depression, stress and immunological activation: the role of cytokines in depressive disorders,” Life Sciences, vol. 62, no. 7, pp. 583–606, 1998. View at: Publisher Site | Google Scholar
  2. R. Dantzer, E. Wollman, L. Vitkovic, and R. Yirmiya, “Cytokines and depression: fortuitous or causative association?” Molecular Psychiatry, vol. 4, no. 4, pp. 328–332, 1999. View at: Publisher Site | Google Scholar
  3. Y.-K. Kim, I.-B. Suh, H. Kim et al., “The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs,” Molecular Psychiatry, vol. 7, no. 10, pp. 1107–1114, 2002. View at: Publisher Site | Google Scholar
  4. J. Licinio and M.-L. Wong, “The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection,” Molecular Psychiatry, vol. 4, no. 4, pp. 317–327, 1999. View at: Publisher Site | Google Scholar
  5. F. Kaestner, M. Hettich, M. Peters et al., “Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity,” Journal of Affective Disorders, vol. 87, no. 2–3, pp. 305–311, 2005. View at: Publisher Site | Google Scholar
  6. M. Maes, W. Stevens, L. DeClerk et al., “Immune disorders in depression: higher T helper/T suppressor-cytotoxic cell ratio,” Acta Psychiatrica Scandinavica, vol. 86, no. 6, pp. 423–431, 1992. View at: Publisher Site | Google Scholar
  7. M. Maes, E. Bosmans, H. Y. Meltzer, S. Scharpe, and E. Suy, “Interleukin-1β: a putative mediator of HPA axis hyperactivity in major depression?” American Journal of Psychiatry, vol. 150, no. 8, pp. 1189–1193, 1993. View at: Google Scholar
  8. M. Maes, W. J. Stevens, L. S. DeClerck et al., “Significantly increased expression of T-cell activation markers (interleukin-2 and HLA-DR) in depression: further evidence for an inflammatory process during that illness,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 17, no. 2, pp. 241–255, 1993. View at: Publisher Site | Google Scholar
  9. M. Maes, “Cytokines in major depression,” Biological Psychiatry, vol. 36, no. 7, pp. 498–499, 1994. View at: Publisher Site | Google Scholar
  10. M. Maes, H. Y. Meltzer, E. Bosmans et al., “Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression,” Journal of Affective Disorders, vol. 34, no. 4, pp. 301–309, 1995. View at: Publisher Site | Google Scholar
  11. A. Seidel, V. Arolt, M. Hunstiger, L. Rink, A. Behnisch, and H. Kirchner, “Increased CD56+ natural killer cells and related cytokines in major depression,” Clinical Immunology and Immunopathology, vol. 78, no. 1, pp. 83–85, 1996. View at: Publisher Site | Google Scholar
  12. F. Brambilla and M. Maggioni, “Blood levels of cytokines in elderly patients with major depressive disorder,” Acta Psychiatrica Scandinavica, vol. 97, no. 4, pp. 309–313, 1998. View at: Publisher Site | Google Scholar
  13. F. Brambilla, P. Monteleone, and M. Maj, “Interleukin-1β and tumor necrosis factor-α in children with major depressive disorder or dysthymia,” Journal of Affective Disorders, vol. 78, no. 3, pp. 273–277, 2004. View at: Publisher Site | Google Scholar
  14. L. L. Carpenter, G. R. Heninger, R. T. Malison, A. R. Tyrka, and L. H. Price, “Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression,” Journal of Affective Disorders, vol. 79, no. 1–3, pp. 285–289, 2004. View at: Publisher Site | Google Scholar
  15. M. Rothermundt, V. Arolt, J. Fenker, H. Gutbrodt, M. Peters, and H. Kirchner, “Different immune patterns in melancholic and non-melancholic major depression,” European Archives of Psychiatry and Clinical Neuroscience, vol. 251, no. 2, pp. 90–97, 2001. View at: Publisher Site | Google Scholar
  16. M. Maes, “Evidence for an immune response in major depression: a review and hypothesis,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 19, no. 1, pp. 11–38, 1995. View at: Publisher Site | Google Scholar
  17. P. J. Neveu and N. Castanon, “Is there evidence for an effect of antidepressant drugs on immune function?” Advances in Experimental Medicine and Biology, vol. 461, pp. 267–281, 1999. View at: Google Scholar
  18. S. Lanquillon, J.-C. Krieg, U. bening-Abu-Shach, and H. Vedder, “Cytokine production and treatment response in major depressive disorder,” Neuropsychopharmacology, vol. 22, no. 4, pp. 370–379, 2000. View at: Publisher Site | Google Scholar
  19. B. E. Leonard, “The immune system, depression and the action of antidepressants,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 25, no. 4, pp. 767–780, 2001. View at: Publisher Site | Google Scholar
  20. M. Kubera, A.-H. Lin, G. Kenis et al., “Anti-inflammatory effects of antidepressants through suppression of the interferon-?/interleukin-10 production ratio,” Journal of Clinical Psychopharmacology, vol. 21, no. 2, pp. 199–206, 2001. View at: Publisher Site | Google Scholar
  21. M. Maes, “The immunoregulatory effects of antidepressants,” Human Psychopharmacology, vol. 16, no. 1, pp. 95–103, 2001. View at: Publisher Site | Google Scholar
  22. R. Weizman, N. Laor, E. Podliszewski et al., “Cytokine production in major depressed patients before and after clomipramine treatment,” Biological Psychiatry, vol. 35, no. 1, pp. 42–47, 1994. View at: Publisher Site | Google Scholar
  23. A. Seidel, V. Arolt, M. Hunstiger, L. Rink, A. Behnisch, and H. Kirchner, “Cytokine production and serum proteins in depression,” Scandinavian Journal of Immunology, vol. 41, no. 6, pp. 534–538, 1995. View at: Publisher Site | Google Scholar
  24. J. Schlatter, F. Ortuño, and S. Cervera-Enguix, “Lymphocyte subsets and lymphokine production in patients with melancholic versus nonmelancholic depression,” Psychiatry Research, vol. 128, no. 3, pp. 259–265, 2004. View at: Publisher Site | Google Scholar
  25. M. Kubera and M. Maes, “Serotonin-immune interactions in major depression,” in Neuro-Immune Interactions in Neurologic and Psychiatric Disorders, P. Patterson, C. Kordon, and Y. Christen, Eds., pp. 79–87, Springer, Berlin, Germany, 2000. View at: Google Scholar
  26. L. Pavón, G. Sandoval-López, M. Eugenia Hernández et al., “Th2 cytokine response in Major Depressive Disorder patients before treatment,” Journal of Neuroimmunology, vol. 172, no. 1–2, pp. 156–165, 2006. View at: Publisher Site | Google Scholar
  27. S. Kanba, H. Manki, F. Shintani, Y. Ohno, G. Yagi, and M. Asai, “Aberrant interleukin-2, receptor-mediated blastoformation of peripheral blood lymphocytes in a severe major depressive episode,” Psychological Medicine, vol. 28, no. 2, pp. 481–484, 1998. View at: Publisher Site | Google Scholar
  28. A. Myint, B. Leonard, H. Steinbusch, and Y. Kim, “Th1, Th2, and Th3 cytokine alterations in major depression,” Journal of Affective Disorders, vol. 88, no. 2, pp. 167–173, 2005. View at: Publisher Site | Google Scholar
  29. B. H. Natelson, T. Denny, X.-D. Zhou et al., “Is depression associated with immune activation?” Journal of Affective Disorders, vol. 53, no. 2, pp. 179–184, 1999. View at: Publisher Site | Google Scholar
  30. K.-M. Lee and Y.-K. Kim, “The role of IL-12 and TGF-β1 in the pathophysiology of major depressive disorder,” International Immunopharmacology, vol. 6, no. 8, pp. 1298–1304, 2006. View at: Publisher Site | Google Scholar
  31. O. Mikova, R. Yakimova, E. Bosmans, G. Kenis, and M. Maes, “Increased serum tumor necrosis factor α concentrations in major depression and multiple sclerosis,” European Neuropsychopharmacology, vol. 11, no. 3, pp. 203–208, 2001. View at: Publisher Site | Google Scholar
  32. C. Tuglu, S. H. Kara, O. Caliyurt, E. Vardar, and E. Abay, “Increased serum tumor necrosis factor-α levels and treatment response in major depressive disorder,” Psychopharmacology, vol. 170, no. 4, pp. 429–433, 2003. View at: Publisher Site | Google Scholar
  33. M. Haack, D. hinze-Selch, T. Fenzel et al., “Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis,” Journal of Psychiatric Research, vol. 33, no. 5, pp. 407–418, 1999. View at: Publisher Site | Google Scholar
  34. S. Rajagopalan, R. Brook, M. Rubenfire et al., “Abnormal brachial artery flow-mediated vasodilation in young adults with major depression,” American Journal of Cardiology, vol. 88, no. 2, pp. 196–198, 2001. View at: Publisher Site | Google Scholar
  35. S. J. Motivala, A. Sarfatti, L. Olmos, and M. R. Irwin, “Inflammatory markers and sleep disturbance in major depression,” Psychosomatic Medicine, vol. 67, no. 2, pp. 187–194, 2005. View at: Publisher Site | Google Scholar

Copyright © 2007 Levent Sutcigil et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views339
Downloads2557
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.